Remdesivir to the rescue: First human examination of possible coronavirus antibody treatment commences in India.

Remdesivir to the rescue: First human examination of possible coronavirus antibody treatment commences in India

 The Indian government has allowed Gilead Sciences Inc’s antiviral drug remdesivir for emergency treatment for five doses in handling Covid-19 victims. As the number of coronavirus cases is exceeding beyond the 6 million-mark globally, scientists and experts are pacing up the struggle to succeed at the potential vaccine for Covid-19.

As a stepping stone in India’s battle in facing Covid-19, New Delhi has allowed Gilead Sciences Inc’s antiviral drug remdesivir for emergency treatment for five doses in handling Covid-19 victims.

Remdesivir, which is managed intravenously in hospital, is the first drug to display improvement in Covid-19 victims in formal clinical trials and is at the lead of the struggle against Covid-19, which has no approved treatment or vaccine. The drug was allowed emergency utility authorization by the US Food and Drug Administration last month and has obtained approval by Japanese health regulators.

Besides the US and India, South Korea has also approved the emergency application of Gilead Sciences Inc’s remdesivir to treat Covid-19. Earlier this week, Gilead announced remdesivir displayed moderate benefit in victims with moderate Covid-19 given a five-day course, while those who took it for 10 days in the study did not prove as well. A senior US Army vaccine researcher told it was right to expect that some kind of coronavirus vaccine could be available to part of the US population by the end of 2020, news agency Reuters announced.

Chairman of Swiss multinational chemicals and biotechnology company, Lonza, announced the group aims to pace up completion of two commercial production lines for Moderna Inc’s trial Covid-19 vaccine.

The first results from the world’s biggest randomised test of drugs to heal Covid-19 patients could be prepared in early July, one of the scientists leading the UK-based study called Recovery stated on Tuesday.

American pharmaceutical company Eli Lilly and Company declared the first human trial of its Covid-19 drug. According to the Indianapolis-based drug-making firm, the drug agent has been extracted from the blood specimen of an early US Covid-19 victim who successfully recovered from the fatal virus.